FDA approves 9th indication for Janssen's Imbruvica
Janssen Pharmaceuticals announced that it has received The Food and Drug Administration’s approval of Imbruvica in combination with rituximab for the treatment of Waldenström’s macroglobulinemia, or WM, a rare blood cancer.